

Material Information (3176 MEDIGEN???????)

SEQ_NO	1	Date of announcement	2024/03/11	Time of announcement	21:14:54
Subject	The Company's 2023 consolidated financial statements have been approved by the Board of Directors				
Date of events	2024/03/11	To which item it meets	paragraph 31		

Statement	<p>1.Date of the board of directors submitted or approved:2024/03/11                  2.Date of the audit committee approved:2024/03/11                  3.Start and end dates of financial reports or unaudited financial information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):                  2023/01/01~2023/12/31                  4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD):1,157,720                  5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):617,329                  6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):-1,233,093                  7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD):-1,278,860                  8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):-1,470,067                  9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):-561,296                  10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):-4.03                  11.Total assets end of the period (thousand NTD):8,527,245                  12.Total liabilities end of the period (thousand NTD):3,530,116                  13.Equity attributable to owners of parent end of the period (thousand NTD):1,591,643                  14.Any other matters that need to be specified: None</p>
-----------	---